SCHEMBL25839637

SCHEMBL25839637

CC(C)C(=O)c1ccc(C(=O)NCCCC(=O)Nc2ccc(C(C)C)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.56
HPGD P15428 1/20 0.54
POLB P06746 1/20 0.53
SIRT2 Q8IXJ6 2/20 0.53
SIRT1 Q96EB6 2/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
RAB9A P51151 2/20 0.52
NPC1 O15118 1/20 0.52
LMNA P02545 1/20 0.52
HDAC4 P56524 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
MEN1 O00255 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25856855 0.88 HDAC3 (0.52) HDAC3HPGDPOLBSIRT2SIRT1
SCHEMBL25855949 0.84 HDAC3 (0.53) HDAC3HPGDPOLBSIRT2SIRT1
SCHEMBL25851766 0.84 HDAC3 (0.47) HDAC3SMN1; SMN2RAB9AHDAC4HDAC1
SCHEMBL25851769 0.84 HDAC3 (0.47) HDAC3SIRT2SIRT1SMN1; SMN2HDAC4
SCHEMBL25836957 0.82 HDAC3 (0.45) HDAC3SMN1; SMN2RAB9AHDAC4HDAC1
SCHEMBL25837253 0.80 HDAC3 (0.48) HDAC3HPGDPOLBSIRT2SIRT1
SCHEMBL25834809 0.78 HDAC3 (0.42) HDAC3SMN1; SMN2RAB9AHDAC4HDAC1
SCHEMBL25092039 0.77 ALDH1A1 (0.50) HDAC3HPGDPOLBSMN1; SMN2RAB9A
SCHEMBL25064118 0.77 NLRP3 (0.58) HPGDPOLBSMN1; SMN2RAB9ANPC1
SCHEMBL25443704 0.76 HDAC3 (0.48) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 HDAC3 1532/4885HPGD 2974/4885POLB 302/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 HDAC3 762/4885HPGD 3988/4885POLB 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.